IPO - Quoin Pharmaceuticals, Ltd.

Form Type: 424B4

Filing Date: 2024-12-23

Corporate Action: Ipo

Type: New

Accession Number: 000110465924131090

Filing Summary: Quoin Pharmaceuticals, Ltd. is conducting an initial public offering (IPO) to issue 3,137,778 ordinary shares represented by American Depositary Shares (ADSs), alongside pre-funded warrants and various series of warrants to acquire additional ordinary shares. The offering price is set at $0.45 per ADS, with accompanying Series F and Series G warrants. The offering also includes pre-funded warrants to purchase 11,973,332 ordinary shares at a slightly reduced price. The warrants provide options with specific exercise prices and expiration terms, creating a comprehensive securities offering. The completion of this offering is aimed at funding ongoing clinical studies for its lead product QRX003, a treatment for Netherton Syndrome, and preparing for its commercialization. Additionally, the company highlights the clinical results from its trials, showcasing positive feedback from patients, which bolsters investor confidence. The expected closing date for this offering is December 23, 2024.

Document Link: View Document